Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 5/20 | 1.00 |
| ▸ | MAOA | P21397 | 4/20 | 1.00 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.68 |
| ▸ | MAOB | P27338 | 2/20 | 0.66 |
| ▸ | CA12 | O43570 | 2/20 | 0.61 |
| ▸ | CA1 | P00915 | 2/20 | 0.61 |
| ▸ | CA2 | P00918 | 2/20 | 0.61 |
| ▸ | CA9 | Q16790 | 2/20 | 0.61 |
| ▸ | DRD2 | P14416 | 2/20 | 0.57 |
| ▸ | DRD4 | P21917 | 2/20 | 0.57 |
| ▸ | DRD3 | P35462 | 2/20 | 0.57 |
| ▸ | CD74 | P04233 | 1/20 | 0.53 |
| ▸ | MIF | P14174 | 1/20 | 0.53 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.50 |
| ▸ | KDM1A | O60341 | 1/20 | 0.50 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17076798 | 0.83 | NOTUM (0.71) | NOTUMMAOAL3MBTL1MAOBCA12 | |
| SCHEMBL27051679 | 0.81 | NOTUM (0.70) | NOTUMMAOAL3MBTL1MAOBCA12 | |
| SCHEMBL28340294 | 0.81 | NOTUM (0.68) | NOTUMMAOAL3MBTL1MAOBCA12 | |
| SCHEMBL2821461 | 0.81 | NOTUM (1.00) | NOTUMMAOAL3MBTL1CA12CA1 | |
| SCHEMBL28064712 | 0.81 | NOTUM (0.68) | NOTUMMAOAL3MBTL1CA12CA1 | |
| SCHEMBL3614213 | 0.81 | NOTUM (0.68) | NOTUMMAOAL3MBTL1DRD2DRD4 | |
| SCHEMBL4434629 | 0.81 | NOTUM (0.68) | NOTUMMAOAL3MBTL1DRD2DRD4 | |
| SCHEMBL3777938 | 0.81 | NOTUM (0.68) | NOTUMMAOAL3MBTL1DRD2DRD4 | |
| SCHEMBL16785617 | 0.80 | NOTUM (0.66) | NOTUMMAOAMAOB | |
| Bromide SCHEMBL1882333 | 0.79 | NOTUM (0.66) | NOTUMMAOAL3MBTL1DRD2DRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240208923-A1 | SMALL MOLECULE INHIBITORS OF MAMMALIAN SLC6A19 FUNCTION | JNANA THERAPEUTICS INC. | 2024-06-27 | — | — | US | disclosed |
| US-11634391-B2 | Compounds which are inhibitors of Notum | UCL BUSINESS LTD (GB) | 2023-04-25 | — | — | US | disclosed |
| US-20210171475-A1 | COMPOUNDS | UCL BUSINESS LTD (GB) | 2021-06-10 | — | — | US | disclosed |
| US-20210171475-A1 | COMPOUNDS | UCL BUSINESS LTD (GB) | 2021-06-10 | — | — | US | disclosed |
| CN-106008474-A | N<2> selective enol ether substituted triazole derivatives and preparation method thereof | 上海大学 | 2016-10-12 | — | — | CN | disclosed |
| WO-2015007613-A1 | O-ALKYL TRIAZOLYL CARBAMATES AS INHIBITORS OF FATTY ACID AMIDE HYDROLASE (FAAH) | FONDAZIONE ISTITUTO ITALIANO DI TECNOLOGIA (IT) | 2015-01-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11634391-B2 | Compounds which are inhibitors of Notum | NOTUM, GOT2, GOT1 | NOTUM 1/4885MAOA 1916/4885L3MBTL1 2093/4885 |
| US-20240208923-A1 | SMALL MOLECULE INHIBITORS OF MAMMALIAN SLC6A19 FUNCTION | SLC18A2, SLC6A19, SLC1A1 | NOTUM 4527/4885MAOA 612/4885L3MBTL1 911/4885 |
| US-20210171475-A1 | COMPOUNDS | GOT2, GOT1, OAT | NOTUM 5/4885MAOA 1386/4885L3MBTL1 1800/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.